Literature DB >> 6798221

Nitroprusside and nitroglycerine in patients with posttraumatic pulmonary failure.

S J Annest, M E Gottlieb, G R Rhodes, W H Paloski, P Barie, J C Newell, D M Shah.   

Abstract

Pulmonary artery pressure is frequently elevated in patients with post-traumatic pulmonary dysfunction. To ascertain whether or not this increase is reversible and what effects such reversal would have on gas exchange, the vasodilators nitroprusside and nitroglycerine were administered to 11 such patients. Pulmonary hemodynamics an gas exchange were observed. Mean pulmonary artery pressure and pulmonary vascular resistance decreased and pulmonary shunt increased. Cardiac output did not change. These results imply that much of the increase in pulmonary artery pressure is due to a reversible restriction of blood flow past unventilated alveoli. Hypoxic vasoconstriction is postulated to be a major cause of the increase in pulmonary artery pressure.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6798221     DOI: 10.1097/00005373-198112000-00004

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  4 in total

Review 1.  Intravenous glyceryl trinitrate (nitroglycerin). A review of its pharmacological properties and therapeutic efficacy.

Authors:  E M Sorkin; R N Brogden; J A Romankiewicz
Journal:  Drugs       Date:  1984-01       Impact factor: 9.546

2.  Endogenous endothelium-derived relaxing factor opposes hypoxic pulmonary vasoconstriction and supports blood flow to hypoxic alveoli in anesthetized rabbits.

Authors:  R S Sprague; C Thiemermann; J R Vane
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

Review 3.  Organ-specific support in multiple organ failure: pulmonary support.

Authors:  P S Barie
Journal:  World J Surg       Date:  1995 Jul-Aug       Impact factor: 3.352

Review 4.  Hypoxic pulmonary vasoconstriction.

Authors:  J T Sylvester; Larissa A Shimoda; Philip I Aaronson; Jeremy P T Ward
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 46.500

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.